Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
AVBP Stock Chart & Stats
$23.05
$0.14(0.52%)
At close: 4:00 PM EST
$23.05
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$15.47 - $30.41
Previous CloseN/A
Volume49.09K
Average Volume (3M)344.18K
Market Cap
$759.04M
Enterprise Value$526.49M
Total Cash (Recent Filing)$300.27M
Total Debt (Recent Filing)$56.00K
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Mar 26, 2026EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding40,568,943
10 Day Avg. Volume299,623
30 Day Avg. Volume344,176
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.25
Price to Sales (P/S)0.00
P/FCF Ratio-11.94
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.36
Forecast
1Y Price Target
$41.29Price Target Upside79.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyFirmonertinib achieved a 78.6% and 46.2% ORR in treatment-naïve and pretreated patients, respectively, in the Phase 1b FAVOUR trial.
Financial StrengthArriVent holds approximately $305.4 million in cash, cash equivalents, and marketable securities, providing a strong cash position.
Regulatory ProgressFirmonertinib has Breakthrough Therapy Designation in the US, indicating a path for accelerated approval.
Bears Say
Clinical RisksClinical risk remains the most significant factor, including the possibility of failure in pivotal trials of firmonertinib or underwhelming efficacy versus standard-of-care.
Financial PerformanceArriVent recorded a 3Q25 net loss of $0.83 per share.
Market SentimentShort interest is notably high at 27.5% of the float.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $15.47 and its highest was $30.41 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $759.04M.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 117 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.789 by -$0.041.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.87.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 40,568,943 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.789. Following the earnings report the stock price went up 3.104%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.29 (79.13% Upside)
$41.29 (79.13% Upside)
Hedge Fund Trend
Increased
By 146.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.70%
12-Months-Change
Fundamentals
Return on Equity
-51.98%
Trailing 12-Months
Asset Growth
-12.74%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. (AVBP) is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer and other serious diseases. The company leverages its expertise in drug development and strategic partnerships to bring advanced therapeutic solutions to the global market.
AVBP Stock 12 Month Forecast
Average Price Target
$41.29
▲(79.13% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
Currently, No data available
---